184 related articles for article (PubMed ID: 4040567)
1. Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat.
Farris FF; King FG; Dedrick RL; Litterst CL
J Pharmacokinet Biopharm; 1985 Feb; 13(1):13-39. PubMed ID: 4040567
[TBL] [Abstract][Full Text] [Related]
2. Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.
King FG; Dedrick RL; Farris FF
J Pharmacokinet Biopharm; 1986 Apr; 14(2):131-55. PubMed ID: 3746636
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
[TBL] [Abstract][Full Text] [Related]
4. The interactions of cis-diamminedichloroplatinum with metallothionein and glutathione in rat liver and kidney.
Suzuki CA; Cherian MG
Toxicology; 1990 Nov; 64(2):113-27. PubMed ID: 1977210
[TBL] [Abstract][Full Text] [Related]
5. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
Siddik ZH; Newell DR; Boxall FE; Harrap KR
Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
[TBL] [Abstract][Full Text] [Related]
6. Cis-diamminedichloroplatinum (II)-procaine pharmacokinetic interaction in mice bearing P388 leukemia.
Esposito M; Vannozzi MO; Viale M; Pellecchia C; Merlo F; Cadoni A; Cafaggi S; Parodi B; Lerza R; Poirier MC
Anticancer Res; 1993; 13(5A):1511-6. PubMed ID: 8239529
[TBL] [Abstract][Full Text] [Related]
7. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro binding of platinum to metallothionein.
Zelazowski AJ; Garvey JS; Hoeschele JD
Arch Biochem Biophys; 1984 Feb; 229(1):246-52. PubMed ID: 6538400
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.
Dedon PC; Borch RF
Biochem Pharmacol; 1987 Jun; 36(12):1955-64. PubMed ID: 2954556
[TBL] [Abstract][Full Text] [Related]
10. Effect of a forced diuresis on the distribution and excretion (via urine and bile) of 195mplatinum when given as 195mplatinum cis-dichlorodiammineplatinum(II).
DeSimone PA; Yancey RS; Coupal JJ; Butts JD; Hoeschel JD
Cancer Treat Rep; 1979 Jun; 63(6):951-60. PubMed ID: 466654
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of cis-dichlorodiammineplatinum.
Gormley PE; Bull JM; LeRoy AF; Cysyk R
Clin Pharmacol Ther; 1979 Mar; 25(3):351-7. PubMed ID: 761445
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin pharmacokinetics: applications of a physiological model.
Farris FF; Dedrick RL; King FG
Toxicol Lett; 1988 Oct; 43(1-3):117-37. PubMed ID: 3051521
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of Cis-dichlorodiammine platinum II, in children after rapid infusion.
Cano JP; Catalin J; Rigault JP; Bues-Charbit M; Placidi M; Raybaud C; Bernard JL
Biomedicine; 1981 Dec; 34(3):146-53. PubMed ID: 7199945
[TBL] [Abstract][Full Text] [Related]
14. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
15. Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II).
Reece PA; Stafford I; Russell J; Gill PG
Cancer Chemother Pharmacol; 1985; 15(3):295-9. PubMed ID: 4053272
[TBL] [Abstract][Full Text] [Related]
16. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics and biotransformation of the analgesic flupirtine in the rat and dog].
Obermeier K; Niebch G; Thiemer K
Arzneimittelforschung; 1985; 35(1):60-7. PubMed ID: 4039153
[TBL] [Abstract][Full Text] [Related]
18. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
19. Biliary excretion of platinum in a patient treated with cis-dichlorodiammineplatinum (II).
Shelley MD; Fish RG; Adams M
Antimicrob Agents Chemother; 1985 Feb; 27(2):275-6. PubMed ID: 4039121
[TBL] [Abstract][Full Text] [Related]
20. The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro.
Melvik JE; Dornish JM; Pettersen EO
Br J Cancer; 1992 Aug; 66(2):260-5. PubMed ID: 1503898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
